Evidence map›Paper›PMID 19041386›Full record

ReviewExperimental gerontology2009

Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review.

Eva Boes, Stefan Coassin, Barbara Kollerits, Iris M Heid, Florian Kronenberg

Open access · greenAbstract readReview
In one paragraph

Review in Experimental gerontology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 3 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 3 syntheses or guidelines pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Sequence Variant Analysis of theInternational journal of molecular sciences · 2023
    Article
  8. Article
  9. Article
  10. Interaction betweenNutrients · 2023
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Association between theBiomedicines · 2020
    Article
  17. Article
  18. Article
  19. Review
  20. HDL in CKD-The Devil Is in the Detail.Journal of the American Society of Nephrology : JASN · 2018
    Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Eva BoesDivision of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Innsbruck, Austria.
Stefan Coassin
Barbara Kollerits
Iris M Heid
Florian Kronenberg
Innsbruck Medical University · ATHelmholtz Zentrum München · DE

Funding

Cell Interactions in the Inflamed Intestinal MucosaR01DK075787 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI JOEL N HIRSCHHORN · 2007 to 2026
$13.1M
NIDDK NIH HHS 1 R01 DK075787-01A1NIDDK NIH HHS R01 DK075787
6 · The paper itself

Abstract

High-density lipoprotein (HDL) particles exhibit multiple antiatherogenic effects. They are key players in the reverse cholesterol transport which shuttles cholesterol from peripheral cells (e.g. macrophages) to the liver or other tissues. This complex process is thought to represent the basis for the antiatherogenic properties of HDL particles. The amount of cholesterol transported in HDL particles is measured as HDL cholesterol (HDLC) and is inversely correlated with the risk for coronary artery disease: an increase of 1mg/dL of HDLC levels is associated with a 2% and 3% decrease of the risk for coronary artery disease in men and women, respectively. Genetically determined conditions with high HDLC levels (e.g. familial hyperalphalipoproteinemia) often coexist with longevity, and higher HDLC levels were found among healthy elderly individuals. HDLC levels are under considerable genetic control with heritability estimates of up to 80%. The identification and characterization of genetic variants associated with HDLC concentrations can provide new insights into the background of longevity. This review provides an extended overview on the current genetic-epidemiological evidence from association studies on genes involved in HDLC metabolism. It provides a path through the jungle of association studies which are sometimes confusing due to the varying and sometimes erroneous names of genetic variants, positions and directions of associations. Furthermore, it reviews the recent findings from genome-wide association studies which have identified new genes influencing HDLC levels. The yet identified genes together explain only a small amount of less than 10% of the HDLC variance, which leaves an enormous room for further yet to be identified genetic variants. This might be accomplished by large population-based genome-wide meta-analyses and by deep-sequencing approaches on the identified genes. The resulting findings will probably result in a re-drawing and extension of the involved metabolic pathways of HDLC metabolism.

Indexed as

Genetic Association StudiesAged, 80 and overApolipoproteinsATP-Binding Cassette TransportersBiological TransportCarboxylic Ester HydrolasesCholesterol Ester Transfer ProteinsCholesterol, HDLCoronary Artery DiseaseDatabases, BibliographicFemaleGenetic Predisposition to DiseaseGenetic VariationGenotypeGhrelinHumansApolipoproteinsATP-Binding Cassette TransportersCarboxylic Ester HydrolasesCholesterol Ester Transfer ProteinsCholesterol, HDLGhrelinPhosphatidylcholine-Sterol O-AcyltransferaseScavenger Receptors, Class B

Identifiers

PMID19041386
PMCPMC2730542
OpenAlexW2163588218

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.